论文部分内容阅读
目的观察用磷酸西格列汀治疗新诊断T2DM的有效性和安全性。方法 139例新诊断T2DM患者,按照HbA1c水平分为A、B、C 3组,采用二肽基肽酶-4(DPP-4)抑制剂磷酸西格列汀100mg,1次/d口服治疗,持续治疗52周。结果治疗52周后,3组HbA1c分别由12.0%、8.4%、6.8%降至7.1%、6.9%、6.5%。FBG、2hBG、胰岛素释放水平与治疗前比较差异均有统计学意义(P<0.05)。肝肾功能、血脂、UAlb、BMI与治疗前比较差异无统计学意义(P>0.05)。有3例发生低血糖事件,未发生其他不良反应。结论用磷酸西格列汀治疗新诊断T2DM患者,可安全有效地降低HbA1c及7个时点(三餐前后、睡前)血糖。
Objective To observe the efficacy and safety of sitagliptin phosphate in newly diagnosed T2DM. Methods One hundred and ninety-three newly diagnosed T2DM patients were divided into A, B and C groups according to the level of HbA1c. The patients were treated with dipeptidyl peptidase-4 (DPP-4) inhibitor sitagliptin phosphate 100mg once daily, Continued treatment for 52 weeks. Results After 52 weeks of treatment, HbA1c in 3 groups decreased from 12.0%, 8.4% and 6.8% to 7.1%, 6.9% and 6.5% respectively. FBG, 2hBG, insulin release levels compared with before treatment were statistically significant differences (P <0.05). There was no significant difference in liver and kidney function, blood lipid, UAlb and BMI between before and after treatment (P> 0.05). Hypoglycemia occurred in 3 cases and no other adverse reactions occurred. Conclusion Sitagliptin phosphate treatment of newly diagnosed T2DM patients can be safely and effectively reduce HbA1c and 7 points (before and after meals, before going to bed) blood sugar.